Medical bottles and syringes are seen with the logo Novo Nordisk shown on the screen in the background.
Nurphoto | Nurphoto | Getty Images
Danish pharmaceutical Behemoth Novo Nordisk On Wednesday, in the fourth quarter, he reported on a net profit from the expected, due to the increase in demand for his obesity drugs.
The net profit for the fourth quarter arrived at 28.23 billion of Danish Crown, opposite 26.09 billion of the Danish crown.
The drug manufacturer has published 107% Annual increase in Wegovy sales at 19.87 billion of the Danish crown (2.76 billion USD) in three months by the end of December, there was a bit lacking 20.02 billion forecasts by Danish Kroner’s forecast by analysts in a survey of facts late Tuesday.
This is the story of the news and will be updated soon.
